At a glance
ClinicalIndex Comparison RecordPhase 1Completed
Drug / intervention
Enfuvirtidedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase I/II Study of T-20, a Fusion Inhibitor, in HIV-1 Infected Children
National Institute of Allergy and Infectious Diseases (NIAID)·interventional·Posted Aug 31, 2001·Updated Nov 1, 2021
In Brief
A Phase 1 clinical trial evaluating Enfuvirtide for HIV Infections. Completed, across 25 sites in 2 countries.
Detailed Summary
The purpose of this study is to determine the best dose of T-20, a new anti-HIV drug, to treat HIV-infected children. T-20, unlike other anti-HIV medications, lessens the ability of HIV to infect certain cells (T cells) in the body. Doctors hope to better treat HIV by adding T-20 to anti-HIV drug combinations that include 1 or 2 nucleoside reverse transcriptase inhibitors (NRTIs) plus a nonnucleoside reverse transcriptase inhibitor (NNRTI) and/or a protease inhibitor (PI).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHIV Infections
CountriesPuerto Rico, United States
Timeline
Phase 1CompletedFinished
200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedAug 2001
Study CompletionDec 2002
TodayJul 2026
First PostedAug 31, 2001
Study CompletionDec 1, 2002
TodayJul 2, 2026
Posted 24.8 years ago
Interventions
Enfuvirtidedrug